Antisecretory treatment: clear-cut benefit and potential risk

• Main Authors: S. I. Pimanov, E. V. Makarenko, E. A. Dikareva
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2018-04-01
• Series: Медицинский совет
• Subjects: proton pump inhibitors; side effects; gastric acid related diseases; gastroduodenal ulcer; gastroesophageal reflux disease; helicobacter pylori; adherence; non-steroidal anti-inflammatory drugs; clopidogrel; esomeprazole
• Online Access: https://www.med-sovet.pro/jour/article/view/2450
• ISSN: 2079-701X; 2658-5790

Proton pump inhibitors (PPI) remain a key element in the management of acid-dependent diseases. The antisecretory drug administration schedule should take into account the nature of the disease and the research data reflected in relevant international consensus. The patient’s adherence to the PPI intake has a significant impact on the results of management of acid-dependent diseases. The benefit of PPI intake significantly exceeds the potential harm that is low or very low. To date, there is no conclusive evidence of the adverse effects of the prolonged use of PPI, however, if there is no indication for the PPI intake, it is not recommended to use high doses of the drug. The pharmacodynamic effect of different PPIs doesn’t differ significantly, however, according to experts’ opinion based on meta-analysis, esomeprazole has some advantage over other drugs.